Therapeutic Target Details
| Target ID: | T24 |
| Target Name: | C-C chemokine receptor type 2 |
| Synonyms: | C-C CKR-2; CMKBR2; MCP-1-R; Monocyte chemoattractant protein 1 receptor; CCR2 |
| GENE: | CCR2 |
| Action: | antagonist |
| Class: | GPCR |
| UniProtKB ID: | P41597 |
| Entry Name: | CCR2_HUMAN |
| Related Drugs: | Cenicriviroc |
| Mechanism: | C-C motif chemokine receptor (CCR) type 2 plays a role in the recruitment, migration and infiltration of proinflammatory monocytes and macrophages at the site of liver injury. C motif chemokine receptor types 2 and 5 are both involved in the inflammatory and fibrogenic pathways. |
| Reference (PMIDs): | 32381514 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0711 | DB05130 | investigational | small molecule | INCB3284 | Target associated | Details |
| R0720 | DB05159 | investigational | small molecule | CCX915 | Therapeutic strategy associated | Details |
| R1452 | DB12520 | investigational | biotech | Plozalizumab | Target associated | Details |
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| B000001 | CHEMBL10 | Small molecule | SB-203580 | 377.44 | C21H16FN3OS | NEUTRAL | Details |
| B000014 | CHEMBL1006 | Small molecule | AMIFOSTINE | 214.23 | C5H15N2O3PS | ZWITTERION | Details |
| B000021 | CHEMBL1009 | Small molecule | LEVODOPA | 197.19 | C9H11NO4 | ZWITTERION | Details |
| B000025 | CHEMBL101 | Small molecule | PHENYLBUTAZONE | 308.38 | C19H20N2O2 | ACID | Details |
| B000032 | CHEMBL101168 | Small molecule | -- | 134.14 | C6H6N4 | NEUTRAL | Details |
| B000049 | CHEMBL1016 | Small molecule | CANDESARTAN | 440.46 | C24H20N6O3 | ACID | Details |
| B000065 | CHEMBL1020 | Small molecule | TOLMETIN | 257.29 | C15H15NO3 | ACID | Details |
| B000075 | CHEMBL1024 | Small molecule | IFOSFAMIDE | 261.09 | C7H15Cl2N2O2P | NEUTRAL | Details |
| B000083 | CHEMBL103 | Small molecule | PROGESTERONE | 314.47 | C21H30O2 | NEUTRAL | Details |
| B000084 | CHEMBL10309 | Small molecule | -- | 441.37 | C23H25BrN2O2 | NEUTRAL | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A06057 | 33025657 | Liver Int | Recent advances targeting C-C chemokine receptor type 2 for liver diseases in monocyte/macrophage. | Details |
| A08073 | 32258142 | Biomed Res Int | Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions. | Details |
| A30847 | 31680767 | Korean J Physiol Pharmacol | Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study. | Details |
| A47009 | 30179264 | Hepatology | Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice. | Details |
| A47734 | 32739404 | Antiviral Res | The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. | Details |
| A51305 | 35749425 | PLoS Pathog | Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. | Details |